US › Healthcare

Foghorn Therapeutics Inc (FHTX)

US · Healthcare · Biotechnology

$4.86+5.42%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$3.3M
Revenue YoY
-45.1%
Net profit
$-19.9M
Profit YoY
-5.5%
EPS
$-0.29
EPS estimate
$-0.31
Net margin
-608.4%

EPS came in at -0.29 against a street estimate of -0.31 — a beat of 6.5%.

Key statistics

Market cap
$266.0M
Forward P/E
0.0
P/B
2,005.35
Book value
$-1.30
EPS (TTM)
$-1.17
52-week high
$6.95
52-week low
$3.27
50-day MA
$4.61
200-day MA
$4.88
Beta
2.86

Analyst view

Analysts rate Foghorn Therapeutics Inc a strong buy (7 buy, 1 hold, 0 sell out of 8) with an average price target of $11.44.

Shareholding

Insiders
14.30%
Institutions
76.73%

Largest institutional holders

FundStake
Flagship Ventures Management, Inc.21.59%
FMR Inc10.30%
Bvf Inc9.95%
Deerfield Management Co7.48%
BlackRock Inc4.03%
Euclidean Capital LLC2.68%
Vanguard Capital Management, LLC2.55%
Geode Capital Management, LLC1.44%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Foghorn Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.